Xencor, Inc Operating Leases, Rent Expense
Xencor, Inc (XNCR) reported Operating Leases, Rent Expense of $2.50 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-02-24
- Xencor, Inc operating leases, rent expense for the quarter ending 2018-12-31 was $600.00K, a 0.00% change year-over-year.
- Xencor, Inc operating leases, rent expense for the quarter ending 2018-09-30 was $700.00K, a 8.19% increase year-over-year.
- Xencor, Inc operating leases, rent expense for the quarter ending 2018-06-30 was $576.00K, a 118.18% increase year-over-year.
- Xencor, Inc operating leases, rent expense for the quarter ending 2018-03-31 was $624.00K, a 230.16% increase year-over-year.
- Xencor, Inc operating leases, rent expense for fiscal 2018 was $2.50M, a 47.06% increase from fiscal 2017.
- Xencor, Inc operating leases, rent expense for fiscal 2017 was $1.70M, a 183.33% increase from fiscal 2016.
- Xencor, Inc operating leases, rent expense for fiscal 2016 was $600.00K, a 7.53% increase from fiscal 2015.
- Xencor, Inc operating leases, rent expense for fiscal 2015 was $558.00K, a 6.53% decline from fiscal 2014.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.30M derived: sum of 2 quarters · filed 2021-02-24 | $1.88M derived: sum of 3 quarters · filed 2021-02-24 | $2.50M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $1.28M derived: sum of 2 quarters · filed 2018-11-05 | $1.90M 10-Q · filed 2018-11-05 | $2.50M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2018-06-30 | $576.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.20M 10-Q · filed 2018-08-07 | $1.80M derived: sum of 3 quarters · filed 2019-02-26 | $2.45M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2018-03-31 | $624.00K 10-Q · filed 2018-05-07 | $1.22M derived: sum of 2 quarters · filed 2019-02-26 | $1.87M derived: sum of 3 quarters · filed 2019-02-26 | $2.13M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $1.25M derived: sum of 2 quarters · filed 2019-02-26 | $1.51M derived: sum of 3 quarters · filed 2019-02-26 | $1.70M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $647.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $911.00K derived: sum of 2 quarters · filed 2018-11-05 | $1.10M 10-Q · filed 2018-11-05 | $1.23M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $453.00K 10-Q · filed 2018-08-07 | $585.00K derived: sum of 3 quarters · filed 2019-02-26 | $755.00K derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | $189.00K 10-Q · filed 2018-05-07 | $321.00K derived: sum of 2 quarters · filed 2019-02-26 | $491.00K derived: sum of 3 quarters · filed 2019-02-26 | $646.00K derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $302.00K derived: sum of 2 quarters · filed 2019-02-26 | $457.00K derived: sum of 3 quarters · filed 2019-02-26 | $600.00K 10-K · filed 2019-02-26 | $638.00K 10-K · filed 2017-03-01 |
| 2016-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $325.00K derived: sum of 2 quarters · filed 2017-11-08 | $468.00K 10-Q · filed 2017-11-08 | $611.00K derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-06-30 | $155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $298.00K 10-Q · filed 2017-08-07 | $441.00K derived: sum of 3 quarters · filed 2018-02-28 | $584.00K derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-03-31 | $143.00K 10-Q · filed 2017-05-10 | $286.00K derived: sum of 2 quarters · filed 2018-02-28 | $429.00K derived: sum of 3 quarters · filed 2018-02-28 | $572.00K derived: sum of 4 quarters · filed 2018-02-28 | |
| 2015-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $286.00K derived: sum of 2 quarters · filed 2018-02-28 | $429.00K derived: sum of 3 quarters · filed 2018-02-28 | $558.00K 10-K · filed 2018-02-28 | |
| 2015-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $286.00K derived: sum of 2 quarters · filed 2016-11-02 | $415.00K 10-Q · filed 2016-11-02 | $570.20K derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $272.00K 10-Q · filed 2016-08-03 | $427.20K derived: sum of 3 quarters · filed 2017-03-01 | $592.00K derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $129.00K 10-Q · filed 2016-05-02 | $284.20K derived: sum of 2 quarters · filed 2017-03-01 | $449.00K derived: sum of 3 quarters · filed 2017-03-01 | $589.00K derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $155.20K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $320.00K derived: sum of 2 quarters · filed 2017-03-01 | $460.00K derived: sum of 3 quarters · filed 2017-03-01 | $597.00K 10-K · filed 2017-03-01 | |
| 2014-09-30 | $164.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $304.80K derived: sum of 2 quarters · filed 2015-11-04 | $441.80K 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | $140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $277.00K 10-Q · filed 2015-08-05 | |||
| 2014-03-31 | $137.00K 10-Q · filed 2015-05-05 | ||||
| 2013-12-31 | $547.00K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |